Omid Hamid, MD, and Ryan Sullivan, MD, discuss new updates in uveal melanoma, and an exciting, recently approved agent for treatment of metastatic disease.
EP. 1: Overview of Metastatic Uveal Melanoma
Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.
EP. 2: Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma
Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.
EP. 3: Recent Trial Data on Tebentafusp in Metastatic Uveal Melanoma
Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.
EP. 4: Managing Tebentafusp Toxicities in Metastatic Uveal Melanoma
Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.
EP. 5: Future Directions in Metastatic Uveal Melanoma Treatment
Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer